-
Incannex Approved For Bioavailability Clinical Trial For Dronabinol-Based Drug For Treatment Of Obstructive Sleep Apnea
Thursday, July 6, 2023 - 10:43am | 558Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee to commence a bioavailability/bioequivalence (‘BA/BE’) clinical trial on IHL-42X, the company’s proprietary drug product for treatment of obstructive sleep...
-
Incannex Reveals Clinical Trial Results On Dronabinol-Based Drug For Obstructive Sleep Apnea
Friday, June 3, 2022 - 10:38am | 677Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), a clinical-stage pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, has completed an analysis of data from the Phase 2 proof-of-concept clinical trial...